RxSight, Inc. (RXST) Operating Margin
- Operating margin · 12 months: Value -45.52%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -45.52% | Operating income / revenue. Period ending 2026-06-30. $-55.11M ÷ $121.08M × 100 ≈ -45.52% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -55.11M USD | Operating Income (Loss) |
| Revenue | 121.08M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 28.71M USD | Cost of Goods and Services Sold |
| Research and development | 36.67M USD | Research and Development Expense |
| Selling, general and administration | 117.31M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-55.11M | $121.08M | $28.71M | $36.67M | $117.31M | -45.52% |
| 2026-03-31 | $-55.35M | $127.48M | $29.30M | $37.65M | $115.87M | -43.42% |
| 2025-12-31 | $-48.19M | $134.48M | $31.47M | $38.55M | $112.65M | -35.84% |
| 2025-09-30 | $-45.48M | $142.09M | $35.55M | $38.85M | $113.17M | -32.01% |
| 2025-06-30 | $-42.53M | $147.06M | $39.53M | $38.63M | $111.43M | -28.92% |
| 2025-03-31 | $-36.86M | $148.31M | $41.72M | $36.70M | $106.75M | -24.85% |
| 2024-12-31 | $-36.86M | $139.93M | $40.98M | $34.37M | $101.43M | -26.34% |
| 2024-09-30 | $-39.08M | $128.29M | $40.48M | $32.50M | $94.39M | -30.46% |
| 2024-06-30 | $-42.37M | $115.18M | $38.86M | $30.77M | $87.92M | -36.79% |
| 2024-03-31 | $-47.66M | $101.10M | $37.02M | $29.87M | $81.87M | -47.14% |
| 2023-12-31 | $-50.09M | $89.08M | $35.31M | $29.05M | $74.80M | -56.23% |
| 2023-09-30 | $-54.22M | $76.58M | $33.05M | $28.39M | $69.36M | -70.80% |
| 2023-06-30 | $-57.67M | $67.00M | $31.84M | $27.68M | $65.15M | -86.07% |
| 2023-03-31 | $-59.84M | $57.55M | $29.62M | $26.47M | $61.30M | -103.97% |
| 2022-12-31 | $-63.32M | $49.01M | $27.68M | $25.98M | $58.66M | -129.21% |
| 2022-09-30 | $-62.99M | $41.34M | $24.57M | $25.22M | $54.55M | -152.36% |
| 2022-06-30 | $-60.15M | $34.51M | $21.75M | $24.20M | $48.70M | -174.27% |
| 2022-03-31 | $-58.23M | $28.05M | $20.89M | $24.57M | $40.81M | -207.59% |
| 2021-12-31 | $-52.79M | $22.59M | $18.08M | $24.50M | $32.80M | -233.64% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-35.41M | $14.68M | $12.97M | $21.93M | $15.18M | -241.26% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |